A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

This study tests a new form of docetaxel (a chemotherapy drug) bound to albumin protein in patients with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. **You may be eligible if...** - You are 18–75 years old with confirmed stomach cancer or cancer of the junction between the stomach and esophagus - Your cancer has worsened after first-line treatment (platinum and fluorouracil-based chemotherapy, with or without immunotherapy) - You have at least one measurable tumor on scans - Your general health is good (ECOG score 0–1) and key organ functions are adequate - You have a life expectancy of at least 3 months - You are willing to use contraception and not donate sperm if male **You may NOT be eligible if...** - You are pregnant or breastfeeding - Your HER2 status is positive but you have not received anti-HER2 therapy - Your major organ function (liver, kidneys, bone marrow) does not meet required minimums - You have previously received docetaxel Talk to your doctor to see if this trial is right for you.